Syros Pharmaceuticals, Inc. (SYRS)
| Market Cap | 10.73K -93.4% |
| Revenue (ttm) | 386.00K -95.6% |
| Net Income | -97.82M |
| EPS | -2.66 |
| Shares Out | 26.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,357 |
| Open | 0.0004 |
| Previous Close | 0.0004 |
| Day's Range | 0.0004 - 0.0004 |
| 52-Week Range | 0.000001 - 0.0200 |
| Beta | 1.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 2, 2026 |
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ... [Read more]
Financial Performance
In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.
Financial StatementsNews
Syros Pharmaceuticals sells Tamibarotene assets to Rege Nephro
Rege Nephro has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals (SYRS), through a mutual agreement. The acquisition was com...
Syros Pharmaceuticals trading resumes
16:35 EST Syros Pharmaceuticals (SYRS) trading resumes
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock
Syros Pharmaceuticals (SYRS) announced that its Board of Directors has approved and the company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market…
Syros Pharmaceuticals trading halted, news pending
16:00 EST Syros Pharmaceuticals (SYRS) trading halted, news pending
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed w...
Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 trial failed to meet its primary endpoint and…
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which…
Syros downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 SELECT-...
Syros Pharmaceuticals downgraded to Hold from Buy at Brookline
Brookline downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy.
Syros Pharmaceuticals trading resumes
17:00 EST Syros Pharmaceuticals (SYRS) trading resumes
Syros Pharmaceuticals says SELECT-MDS-1 trial did not meet primary endpoint
Syros Pharmaceuticals (SYRS) announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) pati...
Syros Pharmaceuticals trading halted, news pending
16:25 EST Syros Pharmaceuticals (SYRS) trading halted, news pending
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies...
Syros Pharmaceuticals Earnings Call Transcript: Q3 2024
Advancement of tamibarotene for higher-risk MDS is on track, with pivotal Phase 3 data expected in mid-November. Q3 2024 saw reduced expenses and a narrowed net loss, with cash reserves projected to fund operations into Q3 2025.
Syros Pharmaceuticals Quarterly report: Q3 2024
Syros Pharmaceuticals has published its Q3 2024 quarterly earnings report on October 31, 2024.
Syros Pharmaceuticals reports Q3 EPS (16c), consensus (72c)
Syros did not recognize revenue in the third quarter, as compared to $3.8M for the third quarter of 2023. The decrease reflects the termination of Syros’ collaboration agreement with Pfizer.
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancie...
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies...
Syros Pharmaceuticals management to meet virtually with Piper Sandler
Virtual Meeting to be held on October 16 hosted by Piper Sandler.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Exicure (XCUR), 397% surge in interest Syros Pharmaceutic...